--- title: "Caribou Biosciences | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 2.397 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285658943.md" datetime: "2026-05-08T03:37:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285658943.md) - [en](https://longbridge.com/en/news/285658943.md) - [zh-HK](https://longbridge.com/zh-HK/news/285658943.md) generator: "portal-rs" --- # Caribou Biosciences | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 2.397 M Revenue: As of FY2026 Q1, the actual value is USD 2.397 M, beating the estimate of USD 2.181 M. EPS: As of FY2026 Q1, the actual value is USD -0.26, beating the estimate of USD -0.315. EBIT: As of FY2026 Q1, the actual value is USD -26.28 M. Caribou Biosciences, Inc. operates as a single reportable and operating segment, focusing on developing allogeneic CAR-T cell therapies . #### Revenue - **Licensing and Other Third-party Revenue**: $2.4 million for the three months ended March 31, 2026, a slight increase from $2.4 million for the same period in 2025 . - **Geographical Disaggregation (Three Months Ended March 31, 2026 vs. 2025)**: - United States: $2.3 million vs. $2.2 million . - Rest of world: $0.1 million vs. $0.1 million . #### Operating Expenses - **Total Operating Expenses**: $28.7 million for the three months ended March 31, 2026, a decrease from $45.3 million for the same period in 2025 . - **Research and Development Expenses**: Decreased by $14.9 million to $20.6 million for the three months ended March 31, 2026, from $35.5 million for the same period in 2025 . This decrease was primarily due to a $7.7 million reduction in external CMO and CRO activities, a $3.0 million decrease in other research and development expenses, a $2.8 million decrease in personnel-related expenses, a $0.9 million decrease in other facilities and allocated expenses, and a $0.5 million decrease in expenses related to licenses, sublicensing revenue, and milestones . - **General and Administrative Expenses**: Decreased by $1.7 million to $8.1 million for the three months ended March 31, 2026, from $9.7 million for the same period in 2025, mainly due to a $1.2 million decrease in personnel-related expenses and a $0.5 million decrease in legal and other service-related expenses . #### Other Income - **Total Other Income**: Decreased by $1.7 million for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to a $1.4 million decrease in interest income from marketable securities . #### Net Loss - **Net Loss**: - $25.1 million for the three months ended March 31, 2026, compared to - $40.0 million for the same period in 2025 . - **Accumulated Deficit**: - $621.6 million as of March 31, 2026 . #### Cash Flow - **Net Cash Used in Operating Activities**: - $27.0 million for the three months ended March 31, 2026, a decrease from - $36.7 million for the same period in 2025 . - **Net Cash Provided by Investing Activities**: $24.0 million for the three months ended March 31, 2026, a decrease from $49.4 million for the same period in 2025, primarily due to decreased proceeds from maturities of marketable securities and higher purchases of marketable securities . - **Net Cash Provided by Financing Activities**: $2.7 million for the three months ended March 31, 2026, an increase from $0.5 million for the same period in 2025, driven by proceeds from the at-the-market (ATM) Sales Agreement . - **Cash, Cash Equivalents, and Marketable Securities**: $118.6 million as of March 31, 2026 . #### Operational Metrics (Clinical Development) - **Vispa-cel (ANTLER Phase 1 Clinical Trial)**: As of September 2, 2025, 84 patients with relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) were enrolled, with the Recommended Phase 2 Dose (RP2D) set at 80x10⁶ viable CAR-T cells . The Optimized Profile Cohort (35 CD19-naïve LBCL patients, as of September 29, 2025) showed an Overall Response Rate (ORR) of 86%, a Complete Response (CR) Rate of 63%, and Progression-Free Survival (PFS) at 12 months of 53% . Safety data for the Optimized Profile Cohort (N=35) indicated no cases of GvHD or Grade 3 or greater immune effector cell-associated neurotoxicity syndrome (ICANS), 1% experienced Grade 3 or greater CRS, and 28% experienced prolonged cytopenias . - **CB-011 (CaMMouflage Phase 1 Clinical Trial)**: As of September 24, 2025, 48 fourth-line or later (4L+) relapsed or refractory multiple myeloma (r/r MM) patients were enrolled in dose escalation, with the Recommended Dose for Expansion (RDE) selected at 450x10⁶ viable CAR-T cells . The RDE Cohort Outcomes (12 BCMA-naïve patients, as of September 24, 2025) reported an ORR of 92%, a CR/stringent CR (sCR) Rate of 75%, and Minimal Residual Disease (MRD) negativity in 91% of evaluable patients . #### Future Outlook and Strategy Caribou Biosciences, Inc. expects its $118.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, to fund operations for at least the next 12 months . The company anticipates continued substantial losses and will require additional capital, likely through equity financing, debt financing, or collaborations, to fund operating expenses, including the planned vispa-cel pivotal Phase 3 trial . Future expenses are projected to increase with clinical trial progression, intellectual property portfolio expansion, and potential commercialization efforts, maintaining reliance on contract manufacturing organizations for clinical trial materials . ### Related Stocks - [CRBU.US](https://longbridge.com/en/quote/CRBU.US.md) ## Related News & Research - [Equifax declares Q3 2026 distribution of R$ 2.02 per unit, payable Sept. 22](https://longbridge.com/en/news/296941296.md) - [Halliburton declares Q3 2026 dividend of R$ 0.59 per unit](https://longbridge.com/en/news/296949616.md) - [Voltalia updates financial calendar with half-year 2026 results release](https://longbridge.com/en/news/296937967.md) - [REG - Utilico Emerging Mkt - Dividend Declaration Q1 2026-27](https://longbridge.com/en/news/296761640.md) - [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**